Peptide Comparison
ImunofanvsThymosin Beta-4
Synthetic hexapeptide derived from thymopoietin with immunomodulatory, antioxidant, and hepatoprotective properties
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
At a Glance
Quick
comparison
Dose Range
Imunofan
50–100 mcg
Thymosin Beta-4
2–5 mg
Frequency
Imunofan
Once daily
Thymosin Beta-4
Twice weekly
Administration
Imunofan
Subcutaneous injection
Thymosin Beta-4
Subcutaneous injection
Cycle Length
Imunofan
8-12 weeks
Thymosin Beta-4
8-12 weeks
Onset Speed
Imunofan
Rapid (hours to days)
Thymosin Beta-4
Moderate (1-2 weeks)
Evidence Level
Imunofan
Limited human trials
Thymosin Beta-4
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Immune
Healing & Recovery
Anti-Aging
Wound Healing
Inflammation Reduction
Tissue Regeneration
Technical Data
Compound
specifications
Imunofan
Molecular Formula
C36H61N13O10
Molecular Weight
836.0 g/mol
Half-Life
Approximately 2-4 hours (intranasal administration)
Bioavailability
~90-95% (subcutaneous injection)
CAS Number
Not assigned (Russian pharmacopeia compound)
Thymosin Beta-4
Molecular Formula
C212H350N56O78S
Molecular Weight
4963
Half-Life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS Number
77591-33-4
Protocols
Dosing
tiers
Imunofan
Thymosin Beta-4
Applications
Best
suited for
Imunofan
Cancer Adjuvant Therapy
Imunofan enhances the body's reserve capacity to inactivate free radicals and oxidants during chemotherapy and radiation, substantially reducing toxic reactions and enabling continuity of cancer treatment. Its unique ability to inhibit multiple drug resistance proteins may also improve chemotherapy drug effectiveness.
Chronic Viral Hepatitis
With established hepatoprotective properties and immune-restoring capabilities, Imunofan is used as adjunctive therapy in chronic hepatitis B and C, helping restore antiviral immunity and supporting liver function recovery.
Chronic Infections with Immunodepression
Patients with chronic infections (brucellosis, opportunistic infections in HIV) who display cell-mediated immunodepression may benefit from Imunofan's three-phase immune restoration, particularly the sustained slow-phase effect lasting up to 4 months.
Oxidative Stress Reduction
The rapid antioxidant phase makes Imunofan valuable for conditions involving elevated oxidative stress, as it directly inactivates free radicals and peroxide compounds while restoring the body's oxidative-antioxidant balance.
Thymosin Beta-4
Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions
Safety Profile
Side
effects
Imunofan
Common
- Injection site reaction
- Transient headache
- Nasal irritation (intranasal form)
- Transient mild fever
- Mild fatigue
- Gastrointestinal discomfort (suppository form)
Uncommon
- Allergic reaction
Serious
- Anaphylactic reaction / Severe hypersensitivity
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Research Status
Safety
& evidence
Imunofan
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Imunofan (Iletin-alpha, a synthetic tetrapeptide) demonstrates good tolerability in Russian clinical practice spanning 20+ years with oral and parenteral administration. Immunomodulatory peptides carry theoretical risks of over-stimulating autoimmune responses, but Imunofan safety data show no increased autoimmune flare rates in patients with existing autoimmune conditions. Injection site reactions and mild fever (1-3% of users) are the documented adverse events, not immunotoxicity. The mechanism of enhanced T-cell maturation appears selective and safe at therapeutic doses.
Contraindications
- xKnown hypersensitivity to imunofan or excipients
- xPregnancy complicated by Rh-conflict (contraindicated)
- xChildren under 2 years of age
- xSevere allergic conditions in acute exacerbation
Thymosin Beta-4
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- xActive systemic infections
- xSevere immunosuppression
- xHypersensitivity to thymosin or any component
- xPregnancy (insufficient safety data)
Decision Guide
Which is
right for you?
Choose Imunofan if...
- Immune system restoration and modulation
- Adjunctive therapy during chemotherapy and radiation
- Support during chronic hepatitis treatment
- Reducing oxidative stress and free radical damage
Choose Thymosin Beta-4 if...
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation